Keytruda To Enjoy First-To-Market Advantage As TNBC Approval Now More Likely
Executive Summary
Merck & Co. unveiled event-free survival data for Keytruda in triple-negative breast cancer, following a failure earlier this year to gain approval on a surrogate endpoint.
You may also be interested in...
Merck’s Solid Quarter Doesn’t Soothe Seagen M&A Watchers
Keytruda- and Gardasil-driven revenue growth exceeded forecasts and Merck expects to keep the PD-1 blockbuster cash coming with earlier-stage indications and a potential subcutaneous formulation.
Keytruda Adds To Women’s Oncology Lead With Endometrial Cancer Data
Published data showed Merck’s PD-1 inhibitor combined with Eisai’s Lenvima improved survival in the all-comer population of previously treated endometrial carcinoma.
Merck & Co.’s Keytruda Gets Fighting Chance In TNBC
The company previously was unsuccessful securing accelerated approval based on complete response data, but event-free survival results may be more persuasive.